Targeting EYA2 tyrosine phosphatase activity in mice with tumors exhibiting a reduced mesenchymal phenotype has been shown to enhance cancer cell immunogenicity, resulting in suppressed tumor growth and improved anti-PD-1 therapeutic response (97). This evidence concerns the gene EYA2 and cancer.